Brazil Approves New Diabetes Drug for 16 Million Patients

Brazil just opened the door for millions of people with diabetes to access a treatment that was previously out of reach.

The country's health authority approved Owozy, a new semaglutide medication for type 2 diabetes, marking a major step toward affordable care in a nation where over 16.5 million people live with the disease. Sandoz will launch the treatment in partnership with Adalvo in the second half of 2026.

The timing couldn't be more critical. Brazil ranks among the countries with the highest diabetes prevalence worldwide, yet one in three people with the condition don't even know they have it. That's more than five million Brazilians walking around undiagnosed, facing serious health risks without treatment.

Even those who know they have diabetes often struggle to access effective medications. High costs and limited availability create barriers that leave patients without the care they need, making this affordable option a potential game changer for millions.

The new medication comes in a pre-filled pen designed to be simple for both patients and healthcare professionals to use. It enters a market worth an estimated $1.8 billion, where demand far exceeds access for many families.

The Ripple Effect

This approval represents more than just one new medication on pharmacy shelves. When affordable treatments reach underserved populations, entire communities benefit from reduced emergency care costs, fewer complications, and healthier, more productive lives.

The medication's arrival could ease the burden on Brazil's healthcare system, which currently struggles to provide adequate diabetes care across the country. Better access to preventive treatment means fewer hospitalizations and emergency interventions down the road.

Sandoz, which provides affordable medicines to over one billion patients globally, sees this as part of a larger mission. The company maintains a portfolio of approximately 1,300 medicines addressing everything from common colds to cancer, generating substantial healthcare savings worldwide.

The approval positions Brazil among the first countries to access this new semaglutide treatment option. As more affordable diabetes medications become available, other nations facing similar public health challenges may follow Brazil's lead in expanding patient access.

For the millions of Brazilians who have waited for accessible diabetes care, help is finally on the way.